Intra-Cellular Therapies (ITCI) Competitors $131.87 0.00 (0.00%) As of 04/2/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ITCI vs. TAK, ARGX, ONC, BNTX, TEVA, SMMT, GMAB, RDY, MRNA, and VTRSShould you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Takeda Pharmaceutical (TAK), argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Intra-Cellular Therapies vs. Takeda Pharmaceutical argenx Beigene BioNTech Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Takeda Pharmaceutical (NYSE:TAK) and Intra-Cellular Therapies (NASDAQ:ITCI) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking. Do analysts rate TAK or ITCI? Intra-Cellular Therapies has a consensus price target of $106.23, suggesting a potential downside of 19.44%. Given Intra-Cellular Therapies' higher probable upside, analysts clearly believe Intra-Cellular Therapies is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk & volatility, TAK or ITCI? Takeda Pharmaceutical has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Do institutionals & insiders have more ownership in TAK or ITCI? 9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has higher earnings & valuation, TAK or ITCI? Takeda Pharmaceutical has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.58T0.01$994.06M$0.4035.73Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Does the MarketBeat Community prefer TAK or ITCI? Intra-Cellular Therapies received 421 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 66.16% of users gave Intra-Cellular Therapies an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10157.06% Underperform Votes7642.94% Intra-Cellular TherapiesOutperform Votes52266.16% Underperform Votes26733.84% Is TAK or ITCI more profitable? Takeda Pharmaceutical has a net margin of 4.53% compared to Intra-Cellular Therapies' net margin of -14.07%. Takeda Pharmaceutical's return on equity of 9.39% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical4.53% 9.39% 4.53% Intra-Cellular Therapies -14.07%-9.93%-8.38% Does the media prefer TAK or ITCI? In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 7 mentions for Takeda Pharmaceutical and 6 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 1.41 beat Takeda Pharmaceutical's score of 0.49 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Intra-Cellular Therapies 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTakeda Pharmaceutical and Intra-Cellular Therapies tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITCI vs. The Competition Export to ExcelMetricIntra-Cellular TherapiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.05B$6.35B$5.35B$7.58BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-151.576.7721.6517.78Price / Sales20.64228.59376.3294.47Price / CashN/A65.6738.1534.64Price / Book21.445.886.443.99Net Income-$139.67M$141.32M$3.20B$247.24M7 Day PerformanceN/A5.18%6.67%5.84%1 Month Performance0.46%-12.93%-6.27%-5.78%1 Year Performance100.17%-14.85%8.56%-1.99% Intra-Cellular Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITCIIntra-Cellular Therapies3.5019 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsTAKTakeda Pharmaceutical2.3626 of 5 stars$14.37-2.4%N/A+6.9%$45.71B$4.58T35.9147,300Gap UpHigh Trading VolumeARGXargenx3.1269 of 5 stars$550.00-0.9%$687.00+24.9%+60.4%$33.42B$2.19B-625.00650High Trading VolumeONCBeigene2.2972 of 5 stars$220.54-7.5%$310.40+40.7%N/A$21.76B$3.81B-26.7610,600Gap UpBNTXBioNTech2.683 of 5 stars$86.82-1.4%$143.44+65.2%+18.3%$20.83B$2.75B-41.343,080Positive NewsGap UpTEVATeva Pharmaceutical Industries3.0066 of 5 stars$13.91+0.8%$23.43+68.5%+2.1%$15.77B$16.54B-9.5936,800Analyst DowngradeOptions VolumeGap UpSMMTSummit Therapeutics2.6255 of 5 stars$17.32-0.2%$35.40+104.4%+613.0%$12.78B$700,000.00-61.85110News CoverageGap UpGMABGenmab A/S4.2212 of 5 stars$18.19-1.1%$41.33+127.2%-34.0%$12.04B$21.53B10.451,660Short Interest ↓Gap UpHigh Trading VolumeRDYDr. Reddy's Laboratories3.0873 of 5 stars$12.59+1.8%$17.00+35.1%-7.2%$10.51B$311.31B20.0424,800Positive NewsHigh Trading VolumeMRNAModerna4.3313 of 5 stars$25.64+2.1%$59.00+130.1%-74.5%$9.91B$3.20B-2.763,900Positive NewsGap UpVTRSViatris2.9578 of 5 stars$7.61-0.1%$10.50+38.0%-32.7%$9.08B$14.74B-10.2837,000High Trading Volume Remove Ads Related Companies and Tools Related Companies TAK Alternatives ARGX Alternatives ONC Alternatives BNTX Alternatives TEVA Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives VTRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITCI) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ITCI Stock Free ITCI Stock Alerts